CMV Clinical Trial
Official title:
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
Completed |
NCT02324244 -
CMV Intensive Care Units
|
N/A | |
Enrolling by invitation |
NCT06263218 -
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
|
||
Recruiting |
NCT04934527 -
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
|
Phase 2 | |
Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06341686 -
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
|
Phase 3 | |
Recruiting |
NCT02136797 -
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Terminated |
NCT02843880 -
Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study
|
N/A | |
Recruiting |
NCT04278547 -
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
|
Phase 4 | |
Recruiting |
NCT06021210 -
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
|
Phase 2 | |
Active, not recruiting |
NCT01633476 -
CMV Modulation of the Immune System in ANCA-associated Vasculitis
|
Phase 2 | |
Suspended |
NCT02988258 -
Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT
|
Phase 1 | |
Recruiting |
NCT03159364 -
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
|
Phase 1/Phase 2 | |
Recruiting |
NCT05089838 -
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
|
Phase 1 | |
Enrolling by invitation |
NCT05656599 -
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
|
||
Completed |
NCT02985775 -
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02083731 -
MSC for Treatment of CMV Infection
|
Phase 2 | |
Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
Recruiting |
NCT03798301 -
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
|
Phase 1 | |
Completed |
NCT02550639 -
Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant
|
Phase 4 |